Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.60 |
| ▸ | GCK | P35557 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585974 | 1.00 | HCAR3 (0.68) | HCAR3SMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL31586440 | 0.89 | HCAR3 (0.61) | HCAR3SMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL5236788 | 0.89 | HCAR3 (0.61) | HCAR3SMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL5231535 | 0.89 | SMN1; SMN2 (0.60) | HCAR3SMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL26406559 | 0.85 | KMT2A (0.59) | SMN1; SMN2RAB9ALMNANPC1TP53 | |
| SCHEMBL5236720 | 0.84 | HCAR3 (0.66) | HCAR3RAB9ANPC1ALDH1A1GCK | |
| SCHEMBL5237722 | 0.83 | ALDH1A1 (0.58) | HCAR3SMN1; SMN2RAB9ALMNATP53 | |
| SCHEMBL5233651 | 0.83 | HCAR3 (0.57) | HCAR3SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL31586306 | 0.83 | HCAR3 (0.57) | HCAR3SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL5233704 | 0.83 | HCAR3 (0.68) | HCAR3SMN1; SMN2RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4056557-B1 | BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS | OTSUKA PHARMA CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4253367-A1 | NOVEL BENZAZEPINE SPIRO DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| EP-3645513-A1 | BENZAZEPINE DERIVATIVES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-110891939-A | Benzazepine derivatives | 大塚制药株式会社 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019004421-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | WO | disclosed |
| US-5719278-A | TREATING EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| US-5700796-A | USEFUL FOR TREATING CONGESTIVE HEART FAILURE, DISEASE CONDITIONS WITH EXCESS RENAL WATER REABSORPTION AND CONDITIONS WITH INCREASED VASULAR RESISTANCE AND CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696112-A | TREATMENT OF CONGESTIVE HEART FAILURE, CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885SMN1; SMN2 4356/4885RAB9A 1412/4885 |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885SMN1; SMN2 4356/4885RAB9A 1412/4885 |
| US-11673878-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885SMN1; SMN2 4356/4885RAB9A 1412/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | HCAR3 742/4885SMN1; SMN2 4154/4885RAB9A 1373/4885 |
| US-10889570-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885SMN1; SMN2 4356/4885RAB9A 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.